Saltar al contenido
Merck
Todas las fotos(3)

Documentos clave

Ver Toda la documentación

SAB4200778

Sigma-Aldrich

Anti-NRAS Antibody

rabbit polyclonal

Sinónimos:

Anti-GTPase NRas, Anti-transforming protein N-Ras

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(3)

About This Item

Código UNSPSC:
12352203
NACRES:
NA.41

Nombre del producto

Anti-NRAS (internal) antibody produced in rabbit, affinity isolated antibody

origen biológico

rabbit

Nivel de calidad

200

forma del anticuerpo

affinity isolated antibody

tipo de anticuerpo

primary antibodies

clon

polyclonal

Formulario

buffered aqueous solution

mol peso

predicted mol wt ~21 kDa

reactividad de especies

human

concentración

~1.0 mg/mL

técnicas

immunoblotting: 2.5-5 μg/mL using human MCF7 cell line extract
immunohistochemistry: 10-20 μg/mL using heat-retrieved formalin-fixed, paraffin-embedded human melanoma sections

Nº de acceso UniProt

P01111

Condiciones de envío

dry ice

temp. de almacenamiento

−20°C

modificación del objetivo postraduccional

unmodified

Información sobre el gen

human ... NRAS(4893)

Descripción general

NRAS, also known as GTPase NRas, Transforming protein N-Ras, or Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, is a member of the Ras protein family, together with KRAS (Kirsten RAS), and HRAS (Harvey RAS), comprising a family of low-molecular-weight GTPases. The Ras family is named for a retrovirus that induced rat sarcomas that were later found to have activating RAS mutations. Ras family proteins serve as molecular switches in regulating pathways that are responsible for diverse cellular processes such as proliferation, differentiation, migration, and apoptosis.3 Ras proteins are highly homologous regarding their primary amino acid sequence and the differences among them concentrated in their C-terminal region. Anti-NRAS (internal) antibody produced in rabbit specifically recognizes human NRAS and does not cross-react with KRAS.

Inmunógeno

Synthetic peptide from the internal region of human NRAS protein, conjugated to KLH

Aplicación

The antibody may be used in various immunochemical techniques including immunoblotting (predicted ∼21 kDa) and immunohistochemistry. Detection of the NRAS band by Immunoblotting is specifically inhibited by the immunizing protein.

Forma física

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide as preservative.

Otras notas

This product is for R&D use only, not for drug, household, or other uses.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Código de clase de almacenamiento

10 - Combustible liquids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
107M4819V
51170903

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Esther Castellano et al.
Genes & cancer, 2(3), 216-231 (2011-07-23)
H-ras, N-ras, and K-ras are canonical ras gene family members frequently activated by point mutation in human cancers and coding for 4 different, highly related protein isoforms (H-Ras, N-Ras, K-Ras4A, and K-Ras4B). Their expression is nearly ubiquitous and broadly conserved
Eva Muñoz-Couselo et al.
OncoTargets and therapy, 10, 3941-3947 (2017-09-02)
Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%-20% of melanomas. The NRAS-mutant subset of melanoma is more
Ha Linh Vu et al.
Pharmacological research, 107, 111-116 (2016-03-19)
Cutaneous melanoma is a devastating form of skin cancer and its incidence is increasing faster than any other preventable cancer in the United States. The mutant NRAS subset of melanoma is more aggressive and associated with poorer outcomes compared to
Douglas B Johnson et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(16), 4186-4192 (2014-06-05)
Successful targeting of specific oncogenic "driver" mutations with small-molecule inhibitors has represented a major advance in cancer therapeutics over the past 10 to 15 years. The most common activating oncogene in human malignancy, RAS (rat sarcoma), has proved to be
Ahmed A Samatar et al.
Nature reviews. Drug discovery, 13(12), 928-942 (2014-12-02)
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK
Ver todos los artículos relacionados

Global Trade Item Number

Número de referencia del producto (SKU)GTIN
SAB4200778-100UL4061833265338

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico